Vanda Pharmaceuticals rises after BLA for rare skin disease treatment

Vanda Pharmaceuticals

15/12/2025 14:53

** Shares of Vanda Pharmaceuticals VNDA.O rise 7.2% to $6.74

** Co submits Biologics License Application (BLA) for imsidolimab to treat generalized pustular psoriasis (GPP), a rare and life-threatening inflammatory skin disease

** Says BLA supported by positive data from late-stage GEMINI-1 and GEMINI-2 trials showing rapid and sustained disease clearance with favorable safety profile

** Vanda requests priority review from FDA citing GPP as a rare orphan disease with significant unmet need; says potential FDA approval due as early as mid-2026

** VNDA stock up 30% YTD, as of last close

 (Reporting by Tharuniyaa Lakshmi in Bengaluru)

 ((tharuniyaa@thomsonreuters.com))